EA200401355A1 - Применение циклопамина при лечении псориаза и других кожных заболеваний - Google Patents

Применение циклопамина при лечении псориаза и других кожных заболеваний

Info

Publication number
EA200401355A1
EA200401355A1 EA200401355A EA200401355A EA200401355A1 EA 200401355 A1 EA200401355 A1 EA 200401355A1 EA 200401355 A EA200401355 A EA 200401355A EA 200401355 A EA200401355 A EA 200401355A EA 200401355 A1 EA200401355 A1 EA 200401355A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclopamine
treatment
corticosteroid
skin
lesions
Prior art date
Application number
EA200401355A
Other languages
English (en)
Inventor
Шинан Таш
Октай Авси
Original Assignee
Шинан Таш
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29247069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200401355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/TR2002/000017 external-priority patent/WO2002078704A1/en
Application filed by Шинан Таш filed Critical Шинан Таш
Publication of EA200401355A1 publication Critical patent/EA200401355A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Фармацевтические композиции, содержащие циклопамин, способствуют преодолению ингибирования дифференцировки клеток кожи. Такие композиции эффективны при лечении болезней, связанных с нарушенной клеточной дифференцировкой. В случае опухолей индукция дифференцировки опухолевых клеток циклопамином обычно сопровождается апоптозом опухолевых клеток, усиливая тем самым терапевтическую эффективность. Эффективность циклопамина при лечении псориаза, обычного заболевания, связанного с нарушением клеточной дифференцировки, значительно повышается при использовании композиций, состоящих из циклопамина и кортикостероида.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401355A 2002-04-19 2003-03-17 Применение циклопамина при лечении псориаза и других кожных заболеваний EA200401355A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/TR2002/000017 WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
PCT/TR2003/000017 WO2003088964A1 (en) 2002-04-19 2003-03-17 Use of cyclopamine in the treatment of psoriasis and other skin disorders

Publications (1)

Publication Number Publication Date
EA200401355A1 true EA200401355A1 (ru) 2005-06-30

Family

ID=29247069

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401355A EA200401355A1 (ru) 2002-04-19 2003-03-17 Применение циклопамина при лечении псориаза и других кожных заболеваний

Country Status (15)

Country Link
US (6) US7605167B2 (ru)
EP (2) EP1411938B1 (ru)
JP (1) JP2006512281A (ru)
KR (4) KR20040102117A (ru)
CN (2) CN1835748A (ru)
AT (1) ATE309802T1 (ru)
AU (1) AU2003230541B2 (ru)
BR (1) BR0309396A (ru)
CA (3) CA2452152A1 (ru)
DE (1) DE60302348T2 (ru)
DK (1) DK1496895T3 (ru)
EA (1) EA200401355A1 (ru)
ES (1) ES2253672T3 (ru)
MX (1) MXPA04010294A (ru)
WO (1) WO2003088964A1 (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
ATE328002T1 (de) 1999-10-13 2006-06-15 Univ Johns Hopkins Med Verbindungen zur regulierung des hedgehog- signalwegs, zusammensetzungen und verwendungen davon
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
DK1401438T3 (da) * 2001-07-02 2006-02-13 Sinan Tas Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
WO2006039569A1 (en) * 2004-09-30 2006-04-13 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
PT1978993T (pt) 2005-10-31 2017-03-17 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro com base em recetores fzd humanos
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1945202A2 (en) * 2005-11-11 2008-07-23 Licentia OY Mammalian hedgehog signaling inhiabitors
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) * 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
AU2008222655B2 (en) 2007-03-07 2014-03-27 Infinity Pharmaceuticals, Inc. Cyclopamine lactam analogs and methods of use thereof
WO2008109184A1 (en) 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
AR070047A1 (es) * 2007-12-27 2010-03-10 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US8716479B2 (en) 2007-12-27 2014-05-06 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110135739A1 (en) * 2009-11-06 2011-06-09 Bennett Carter Oral Formulations of a Hedgehog Pathway Inhibitor
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP2950885B1 (en) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
AU2016271468B2 (en) * 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
US11424772B2 (en) 2018-12-06 2022-08-23 Berex, Inc. Receiver architectures with parametric circuits
EP4358955A1 (en) * 2021-06-21 2024-05-01 Palvella Therapeutics, Inc. Methods and compositions for treating gorlin syndrome
IL311367A (en) 2021-09-13 2024-05-01 Sinan Ta? Effective interventions in aging and controversies related to human aging and their outcomes

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649923A5 (de) * 1980-10-06 1985-06-28 Glaxo Group Ltd Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide.
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
DE69841320D1 (de) 1997-02-10 2010-01-07 Harvard College Verfahren zur modulation von hämatopoese und vaskulärem wachstum
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US20050130922A1 (en) * 1997-06-20 2005-06-16 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
CA2326654C (en) * 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
JP2003501395A (ja) * 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
US20050080138A1 (en) * 1999-09-16 2005-04-14 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
ATE328002T1 (de) * 1999-10-13 2006-06-15 Univ Johns Hopkins Med Verbindungen zur regulierung des hedgehog- signalwegs, zusammensetzungen und verwendungen davon
US6552016B1 (en) * 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6951839B1 (en) * 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
EP1646395B8 (en) * 1999-11-30 2014-12-17 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683108B1 (en) * 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
WO2001098344A2 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CU23175A1 (es) 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
AU9684401A (en) * 2000-10-13 2002-04-22 Curis Inc Hedgehog antagonists, methods and uses related thereto
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20020165221A1 (en) * 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
DK1401438T3 (da) * 2001-07-02 2006-02-13 Sinan Tas Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
RU2322984C2 (ru) * 2001-10-05 2008-04-27 Комбинаторкс, Инкорпорейтед Комбинации для лечения иммуновоспалительных расстройств
US6927205B2 (en) * 2003-04-28 2005-08-09 Procyte Corporation Compositions and methods for treatment of psoriasis
KR20050037103A (ko) 2003-10-17 2005-04-21 주식회사 엘지생활건강 피부 미백용 화장료 조성물
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
JP5435946B2 (ja) * 2005-08-22 2014-03-05 ジョンズ ホプキンス ユニバーシティ 疾患を処置するためのヘッジホッグ経路アンタゴニスト

Also Published As

Publication number Publication date
KR20080096605A (ko) 2008-10-30
US9757361B2 (en) 2017-09-12
US20100048725A2 (en) 2010-02-25
KR20070108287A (ko) 2007-11-08
US20080089915A1 (en) 2008-04-17
DE60302348T2 (de) 2006-07-27
CN1835748A (zh) 2006-09-20
EP1496895A1 (en) 2005-01-19
AU2003230541B2 (en) 2006-06-29
CA2636960A1 (en) 2003-10-30
DE60302348D1 (de) 2005-12-22
US20040072913A1 (en) 2004-04-15
AU2003230541A1 (en) 2003-11-03
DK1496895T3 (da) 2006-03-27
BR0309396A (pt) 2005-02-09
ATE309802T1 (de) 2005-12-15
US7605167B2 (en) 2009-10-20
EP1411938B1 (en) 2005-07-06
US20080090790A1 (en) 2008-04-17
CA2636960C (en) 2013-12-31
US7629352B2 (en) 2009-12-08
CA2452152A1 (en) 2002-10-10
KR20080094739A (ko) 2008-10-23
US20110104254A1 (en) 2011-05-05
US7893078B2 (en) 2011-02-22
US20090286822A1 (en) 2009-11-19
CN101642458A (zh) 2010-02-10
KR20040102117A (ko) 2004-12-03
EP1496895B1 (en) 2005-11-16
CA2481499A1 (en) 2003-10-30
US8025893B2 (en) 2011-09-27
ES2253672T3 (es) 2006-06-01
JP2006512281A (ja) 2006-04-13
EP1411938A1 (en) 2004-04-28
US20040072914A1 (en) 2004-04-15
MXPA04010294A (es) 2005-05-17
CA2481499C (en) 2013-05-21
WO2003088964A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
EA200401355A1 (ru) Применение циклопамина при лечении псориаза и других кожных заболеваний
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
HK1102991A1 (en) Pharmaceutical formulation of decitabine
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
EA200500149A1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
Joseph et al. Unilateral remission of psoriasis following traumatic nerve palsy
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
DK1558265T3 (da) Anvendelse af dropspirenon til behandling af hypertension
WO2003056899A3 (en) Nitric oxide donors for treatment of disease and injury
EP4357345A1 (en) Cly series compound, preparation method therefor and use thereof in preparation of drugs
ATE320797T1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization
Simman et al. Cultured palmar keratinocytes after auto-engraftment to plantar surface maintain site and function specificity
CA2382315A1 (en) Antineoplastic extract from achillea millefolium